Thus, we offered that the MMP-9 in cancer cells should be constructed as a novel target for an anticancer drug to treat malignant phenotype tumors, which are mainly characterized by HER2-positive and TNBC subtypes (Mehner et al., 2014; Yousef et al., 2014). This evidence concerns the gene ERBB2 and cancer.